122 related articles for article (PubMed ID: 37505210)
21. Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines.
Zou Z; Xie L; Wei J; Yu L; Qian X; Chen J; Wang T; Liu B
BMC Complement Altern Med; 2012 Apr; 12():58. PubMed ID: 22546220
[TBL] [Abstract][Full Text] [Related]
22. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
23. Tumor microcalcification-mediated relay drug delivery for photodynamic immunotherapy of breast cancer.
Jian H; Wang X; Song P; Wu X; Zheng R; Wang Y; Zhang H
Acta Biomater; 2022 Mar; 140():518-529. PubMed ID: 34923096
[TBL] [Abstract][Full Text] [Related]
24. Studies on lactoferrin nanoparticles of gambogic acid for oral delivery.
Zhang ZH; Wang XP; Ayman WY; Munyendo WL; Lv HX; Zhou JP
Drug Deliv; 2013 Feb; 20(2):86-93. PubMed ID: 23495734
[TBL] [Abstract][Full Text] [Related]
25. "Guide" of muscone modification enhanced brain-targeting efficacy and anti-glioma effect of lactoferrin modified DTX liposomes.
Qi N; Duan W; Gao D; Ma N; Zhang J; Feng J; Li A
Bioeng Transl Med; 2023 Mar; 8(2):e10393. PubMed ID: 36925685
[TBL] [Abstract][Full Text] [Related]
26. Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery.
Zheng Z; Zhang J; Jiang J; He Y; Zhang W; Mo X; Kang X; Xu Q; Wang B; Huang Y
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817393
[TBL] [Abstract][Full Text] [Related]
27. Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1.
Wang H; Tang Y; Fang Y; Zhang M; Wang H; He Z; Wang B; Xu Q; Huang Y
Nano Lett; 2019 May; 19(5):2935-2944. PubMed ID: 30950276
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of lyophilised egg PC liposomes incorporating curcumin and evaluation of its activity against colorectal cancer cell lines.
Pandelidou M; Dimas K; Georgopoulos A; Hatziantoniou S; Demetzos C
J Nanosci Nanotechnol; 2011 Feb; 11(2):1259-66. PubMed ID: 21456169
[TBL] [Abstract][Full Text] [Related]
29. Oral Administration of Liposome-Apatinib and Locally Delivery of Docetaxel/MPEG-PCL by Fibrin Glue Synergistically Improve Therapeutic Effect in Colorectal Cancer.
Yu T; Wu C; Zhu C; He Y; Yang D; Cheng Y; Gao X
J Biomed Nanotechnol; 2018 Dec; 14(12):2077-2091. PubMed ID: 30305215
[TBL] [Abstract][Full Text] [Related]
30. Astragaloside IV Exerts Anti-tumor Effect on Murine Colorectal Cancer by Re-educating Tumor-Associated Macrophage.
Liu F; Ran F; He H; Chen L
Arch Immunol Ther Exp (Warsz); 2020 Oct; 68(6):33. PubMed ID: 33095374
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells.
Zhu Y; Wang A; Zhang S; Kim J; Xia J; Zhang F; Wang D; Wang Q; Wang J
J Adv Res; 2023 Jul; 49():159-173. PubMed ID: 36167294
[TBL] [Abstract][Full Text] [Related]
32. Liposome technologies towards colorectal cancer therapeutics.
Sang R; Stratton B; Engel A; Deng W
Acta Biomater; 2021 Jun; 127():24-40. PubMed ID: 33812076
[TBL] [Abstract][Full Text] [Related]
33. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer.
Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z
J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609
[TBL] [Abstract][Full Text] [Related]
34. Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer.
Zhang Z; Lu M; Chen C; Tong X; Li Y; Yang K; Lv H; Xu J; Qin L
Theranostics; 2021; 11(7):3167-3182. PubMed ID: 33537080
[No Abstract] [Full Text] [Related]
35. A solvent-assisted active loading technology to prepare gambogic acid and all-trans retinoic acid co-encapsulated liposomes for synergistic anticancer therapy.
Na K; Liu K; Yu J; Wang X; Li M; Tian C; He H; He Y; Wang Y
Drug Deliv Transl Res; 2020 Feb; 10(1):146-158. PubMed ID: 31529371
[TBL] [Abstract][Full Text] [Related]
36. Magnetism-mediated targeting hyperthermia-immunotherapy in "cold" tumor with CSF1R inhibitor.
Fang Y; He Y; Wu C; Zhang M; Gu Z; Zhang J; Liu E; Xu Q; Asrorov AM; Huang Y
Theranostics; 2021; 11(14):6860-6872. PubMed ID: 34093858
[No Abstract] [Full Text] [Related]
37. Enhanced chemotherapeutic efficacy of apigenin liposomes in colorectal cancer based on flavone-membrane interactions.
Banerjee K; Banerjee S; Mandal M
J Colloid Interface Sci; 2017 Apr; 491():98-110. PubMed ID: 28012918
[TBL] [Abstract][Full Text] [Related]
38. Tumor-targeted liposomes with platycodin D2 promote apoptosis in colorectal cancer.
Cho E; Mun SJ; Jeon M; Kim HK; Baek H; Ham YS; Gil WJ; Kim JW; Yang CS
Mater Today Bio; 2023 Oct; 22():100745. PubMed ID: 37576871
[TBL] [Abstract][Full Text] [Related]
39. Comparison of anticancer activity between lactoferrin nanoliposome and lactoferrin in Caco-2 cells in vitro.
Ma J; Guan R; Shen H; Lu F; Xiao C; Liu M; Kang T
Food Chem Toxicol; 2013 Sep; 59():72-7. PubMed ID: 23743119
[TBL] [Abstract][Full Text] [Related]
40. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma.
Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR
Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
